A phase I clinical trial (ClinicalTrials.gov Identifier: NCT02215850) of SLC-0111, a selective inhibitor of both CAIX and CAXII, demonstrated safety in 17 patients with advanced solid tumors across 10 different cancer types. This evidence concerns the gene CA9 and cancer.